Results 81 to 90 of about 30,839 (241)

Bosutinib in the management of chronic myelogenous leukemia

Biologics: Targets & Therapy, 2013
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj  

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Clinical and Translational Science, Volume 18, Issue 3, March 2025.
ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis
Andrew G. Hadd, Angela Silvestro, Brittany Avin McKelvey, Jonathan Baden, Christina Bormann Chung, Ben Brown, Fernando Cruz‐Guilloty, James Godsey, Gregory Jones, Cheng‐Ho Jimmy Lin, Dorys Lopez Ramos, Daniel Norton, Melanie R. Palomares, Carol Pena, Thereasa Rich, Angel Rodriguez, Mark Stewart, Diana Merino Vega, Lauren C. Leiman   +18 more
wiley   +1 more source

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia [PDF]

, 2017
Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30-40% of patients develop resistance to imatinib therapy.
Bandyopadhyay, Shovik, Cheng, Ji-Xin, Li, Junjie, Oh, Stephen T, Traer, Elie, Tyner, Jeffrey W, Zhou, Amy   +6 more
core   +4 more sources

ACUTE UNDIFFERENTIATED LEUKEMIA WITH BCR-ABL TRANSLOCATION: CASE REPORT AND LITERATURE REVIEW

Hematology, Transfusion and Cell Therapy, 2021
The 2016 WHO classification defines acute undifferentiated leukemia (AUL) as a rare type of acute leukemia (AL) without defining markers for either lymphoid or myeloid lineage commitment.
AC Cortez, AD Costa, VDA Bovolenta, MM Nascimento, J Schmidt-Filho, DRA Silveira   +5 more
doaj  

Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience [PDF]

, 2011
Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by
Akagi, Tomoaki, Kaimori, Mitsuomi, Kubo, Kohmei, Mariya, Yasushi, Ogura, Kazuto, Oshikiri, Toshiyuki, Sakamoto, Yuichi, Sasaki, Sumiko, Segawa, Megumi, Teshiromori, Ryuichi   +9 more
core   +1 more source

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Food Science &Nutrition, Volume 13, Issue 2, February 2025.
Illustrating the mechanism of Proteolysis Targeting Chimeras (PROTACs), development of ligands available for PROTACs, PROTACs targeting cancers, and its advantages. PROTACs offer a versatile strategy for personalized cancer treatment ABSTRACT Proteolysis Targeting Chimeras (PROTACs) have revolutionized cancer therapy by offering a selective and ...
Saooda Ibrahim, Muhammad Umer Khan, Iqra Khurram, Raima Rehman, Abdur Rauf, Zubair Ahmad, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Mohammed Mansour Quradha   +8 more
wiley   +1 more source

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

Diagnosis and typing of leukemia using a single peripheral blood cell through deep learning

Cancer Science, Volume 116, Issue 2, Page 533-543, February 2025.
This pioneering research investigates the manner in which cellular morphological responses are linked to the nature of genome information using deep learning. Abstract Leukemia is highly heterogeneous, meaning that different types of leukemia require different treatments and have different prognoses.
Geng Yan, Gao Mingyang, Shi Wei, Liang Hongping, Qin Liyuan, Liu Ailan, Kong Xiaomei, Zhao Huilan, Zhao Juanjuan, Qiang Yan   +9 more
wiley   +1 more source

Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]

Journal of Lipid Research, 2013
Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns, Marimuthu Subathra, Paola Signorelli, Young Choi, Xiaofeng Yang, Yong Wang, Maristella Villani, Kapil Bhalla, Daohong Zhou, Chiara Luberto   +9 more
doaj